跳至主要内容
临床试验/ACTRN12616001000493
ACTRN12616001000493已完成未知

A national multicentre clinical trial to assess the feasibility of performing genomic testing of rare cancers to match the cancer to treatment.

Melbourne Health0 个研究点目标入组 100 人开始时间: 2016年7月28日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • * Patients aged over 18 years, with signed informed consent and ability to comply with protocol requirements
  • * Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • * Patients with a life expectance of >12 weeks
  • * Access to tumour tissue is available from core biopsy or surgical resection from a disease site
  • * Histologically confirmed rare histopathology diagnosis according to the RARECARE group definition
  • * Malignancy where little evidence-based care or standard of care therapies exist
  • * Tumour type associated with a poor outcome

排除标准

  • * Patients who are unable, or unwilling to consent to the study.
  • * Patients who have a concurrent active malignancy other than adequately treated non-melanomatous skin cancer, early prostatic adenocarcinoma treated with curative intent or non-invasive carcinoma / in-situ neoplasm of the cervix or breast. Patients with a previous history of malignancy will be eligible provided they have been disease-free for >5 years.

研究者

相似试验

A study to evaluate the feasibility of performing... | 临床试验